Abstract: The instant disclosure provides antibodies that specifically bind to ApoC3 (e.g., human ApoC3) and antagonize ApoC3 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.

Abstract: The instant disclosure provides antibodies that specifically bind to ApoC3 (e.g., human ApoC3) and antagonize ApoC3 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.

Abstract: The instant disclosure provides antibodies that specifically bind to ApoC3 (e.g., human ApoC3) and antagonize ApoC3 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.

Abstract: The instant disclosure provides antibodies that specifically bind to ApoC3 (e.g., human ApoC3) and antagonize ApoC3 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.

Abstract: The instant disclosure provides antibodies that specifically bind to ApoC3 (e.g., human ApoC3) and antagonize ApoC3 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.

Abstract: The instant disclosure provides antibodies that specifically bind to ApoC3 (e.g., human ApoC3) and antagonize ApoC3 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.

Abstract: The instant disclosure provides antibodies that specifically bind to ApoC3 (e.g., human ApoC3) and antagonize ApoC3 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.

Abstract: The instant disclosure provides antibodies that specifically bind to ApoC3 (e.g., human or cynomolgus ApoC3) and antagonizes ApoC3 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.

Abstract: The instant disclosure provides antibodies that specifically bind to ApoC3 (e.g., human ApoC3) and antagonize ApoC3 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.

Abstract: The instant disclosure provides antibodies that specifically bind to ApoC3 (e.g., human ApoC3) and antagonize ApoC3 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.

Abstract: The instant disclosure provides antibodies that specifically bind to ApoC3 (e.g., human ApoC3) and antagonize ApoC3 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.

Abstract: The instant disclosure provides antibodies that specifically bind to ApoC3 (e.g., human ApoC3) and antagonize ApoC3 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.

Abstract: The instant disclosure provides antibodies that specifically bind to ApoC3 (e.g., human ApoC3) and antagonize ApoC3 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.

Abstract: The instant disclosure provides antibodies that specifically bind to ApoC3 (e.g., human ApoC3) and antagonize ApoC3 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.

Abstract: The instant disclosure provides antibodies that specifically bind to ApoC3 (e.g., human ApoC3) and antagonize ApoC3 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.

Abstract: A method of using a shielding device with an applicator includes inserting the distal portion of the shielding device to a treatment site of a patient, the shield being made of plastic, imaging the treatment site, planning treatment of the treatment site based on the imaging, setting up the patient for treatment, imaging the treatment site, removing the distal portion of the shielding device from the treatment site, exchanging the shield made of plastic with a shield made of tungsten, inserting the distal portion of the shielding device to the treatment site, the shield being made of tungsten, imaging the treatment site, and performing the treatment.

Abstract: A shielding device includes two elongated, parallel tubes joined at a distal portion, and a shield at least one of removably and slidably situated at the distal portion. An assembly includes an applicator configured for a treatment site, an assembly block attached to the applicator, at least one rotary unit configured to be rotatably received in the assembly block, and at least one shielding device that is configured to be movably received in a respective rotary unit. A method of using the shielding device with an applicator includes inserting the distal portion of the shielding device to a treatment site, and adjusting a position of the distal portion relative to a distal end of the applicator.

Abstract: A shielding device includes two elongated, parallel tubes joined at a distal portion, and a shield at least one of removably and slidably situated at the distal portion. An assembly includes an applicator configured for a treatment site, an assembly block attached to the applicator, at least one rotary unit configured to be rotatably received in the assembly block, and at least one shielding device that is configured to be movably received in a respective rotary unit. A method of using the shielding device with an applicator includes inserting the distal portion of the shielding device to a treatment site, and adjusting a position of the distal portion relative to a distal end of the applicator.

Abstract: A method of using a shielding device with an applicator includes inserting the distal portion of the shielding device to a treatment site of a patient, the shield being made of plastic, imaging the treatment site, planning treatment of the treatment site based on the imaging, setting up the patient for treatment, imaging the treatment site, removing the distal portion of the shielding device from the treatment site, exchanging the shield made of plastic with a shield made of tungsten, inserting the distal portion of the shielding device to the treatment site, the shield being made of tungsten, imaging the treatment site, and performing the treatment.

Abstract: A device and method for retaining a position of a treatment applicator include a perineal retainer body configured to receive the applicator and form a positive stop with a perineum of a body of a patient, and a locking bracket configured to secure the perineal retainer body to the applicator. The locking bracket is movable between first and second positions with respect to the perineal retainer body, is configured to exert a clamping force to clamp the applicator, includes an actuator configured to move the locking bracket between the first and second positions, and is vertically accessible for securing and adjusting the applicator with respect to the perineal retainer body. The method includes securing a perineal retainer body to the applicator by a locking bracket, and attaching the perineal retainer body to a body of a patient.